649735-41-1

Basic information

• Product Name: 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol
• Synonyms: 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol;4-(4-fluoro-2-Methyl-1H-indol-5-yloxy)- 5-Methylpyrrolo[1,2-f][1,2,4]triazin-6-ol;4-(4-fluoro-2-Methyl-1H-indol-5-yloxy)-5-Methylpyrrolo[2,1-f][1,2,4]triazin-6-ol, 4-(4-fluoro-2-Methyl-1H-indol-5-yloxy)-5-Methyl-pyrrolo[2,1-f][1,2,4]triazin-6-ol
• CAS NO: 649735-41-1
• Molecular Formula: C₁₆H₁₃FN₄O₂
• Molecular Weight: 312.2984232
• Mol File: 649735-41-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.51
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol(649735-41-1)
• EPA Substance Registry System: 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol(649735-41-1)

Safety Data

• Hazardous Substances Data: 649735-41-1(Hazardous Substances Data)

Usage

General Description

4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol is a chemical compound with a complicated and lengthy molecular structure. It is a pyrrolo[2,1-f][1,2,4]triazin-6-ol derivative that contains a fluorine-substituted 2-methyl-1H-indol-5-yl group and a 5-methylpyrrolo moiety. 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol may have potential therapeutic applications due to its unique structure, but further research and testing would be required to determine its specific properties and potential uses.

Upstream product

• 649736-31-2 1-(2-fluoro-3-hydroxy-6-nitrophenyl)propan-2-one 
• 288385-99-9 1-(2-fluoro-3-methoxy-6-nitrophenyl)propan-2-one 
• 1638768-25-8 C₁₇H₁₃FN₄O₂ 
• 649736-29-8 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 121247-16-3 1-(2,3-difluoro-6-nitrophenyl)propan-2-one 
• 427878-41-9 4-chloro-5-methyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 1022112-32-8 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoic acid ethyl ester 
• 771-69-7 2,3,4-trifluoronitrobenzene 
• 649736-30-1 2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)propan-2-ol 
• 649736-26-5 6-(benzyloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-ol 
• 649736-27-6 6-(benzyloxy)-4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine 
• 310444-84-9 4-Phenoxy-5-methyl-6-hydroxypyrrolo[2,1-f][1,2,4]triazine 
• 886585-68-8 6-(benzyloxy)-5-methyl-4-phenoxypyrrolo[2,1-f][1,2,4]triazine 

Downstream Products

• 649735-46-6 Brivanib 

Relevant articles and documents

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor

A series of substituted 4-(4-fluoro-1H-indol-5-yloxy)pyrrolo-[2.1-f][1,2,4] triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is reported. Structure-activity relationship studies revealed that a methyl group at the 5-position and a substituted alkoxy group at the 6-position of the pyrrolo[2,1-f][1,2,4]triazine core gave potent compounds. Biochemical potency, kinase selectivity, and pharmacokinetics of the series were optimized and in vitro safety liabilities were minimized to afford BMS-540215 (12), which demonstrated robust preclinical in vivo activity in human tumor xenograft models. The L-alanine prodrug of 12, BMS-582664 (21), is currently under evaluation in clinical trials for the treatment of solid tumors.